CD86 and congenital rubella syndrome: Our results indicate that converting the negative CTLA4-CD86/CD86 signal leads to improved antitumor activity without eliciting severe GVHD and CRS, suggesting that CTLA4-CAR could be employed to improve CAR T cell efficacy.